Literature DB >> 6249480

Chemotherapy for adenocystic carcinoma.

I F Tannock, D J Sutherland.   

Abstract

Seventeen patients with adenocystic carcinoma have received 34 adequate trials of chemotherapy at Princess Margaret Hospital since 1969. There have been five objective responses to chemotherapy in 4 cases, lasting from five to 24 months, and 3 other patients have had stabilized disease for a period of five to seven months. Responding and stabilized patients all had symptomatic improvement. Most responses were to 5-fluorouracil, the preferred drug for initial treatment of metastatic disease or locoregional disease that cannot be controlled by means of surgery or radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249480     DOI: 10.1002/1097-0142(19800801)46:3<452::aid-cncr2820460305>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Adenoid cystic carcinoma of the skull base.

Authors:  P R Issing; I Hemmanouil; T Stöver; H G Kempf; L Wilkens; R Heermann; T Lenarz
Journal:  Skull Base Surg       Date:  1999

Review 2.  Chemotherapeutic management of head and neck cancer.

Authors:  M Al-Sarraf
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Image-guided volumetric modulated arc therapy (IG-VMAT) for unresectable ACC of the trachea: a feasible curative option.

Authors:  Rahul Lal Chowdhary; Kundan Singh Chufal; Anjali Kakria Pahuja; Manindra Bhushan; Rajpal Singh; Irfan Ahmad
Journal:  BMJ Case Rep       Date:  2019-03-21

4.  A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

Authors:  Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S Axelrod; Ronald C Deconti; Arlene A Forastiere
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

Review 5.  Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.

Authors:  Luana Guimaraes de Sousa; Katarina Jovanovic; Renata Ferrarotto
Journal:  Curr Treat Options Oncol       Date:  2022-07-19

Review 6.  Systemic therapies for salivary gland adenoid cystic carcinoma.

Authors:  Sosuke Sahara; Alexandra E Herzog; Jacques E Nör
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

Review 7.  Chemotherapy for cranial base tumors.

Authors:  H E Jacob
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Systemic therapy in the management of metastatic or advanced salivary gland cancers.

Authors:  Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Journal:  Head Neck Oncol       Date:  2012-05-04

Review 9.  Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature.

Authors:  Sophia Rizk; Annie Robert; Annick Vandenhooft; Mario Airoldi; Gabriela Kornek; Jean-Pascal Machiels
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-04-06       Impact factor: 3.236

10.  A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.

Authors:  A S Jones; D E Phillips; J A Cook; T R Helliwell
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.